Table 1.
Comparison of the Clinicopathologic Parameters Between the Treated and Control Groups
| Parameters | Treated group (n=218) | Control group (n=65) | P value |
|---|---|---|---|
| Median age at diagnosis (range, years) | 63.0 (38.9 – 85.4) | 61.2 (24.9 – 80.9) | 0.48 |
| Gender | 0.67 | ||
| Male | 129 (59.2%) | 36 (55.4%) | |
| Female | 89 (40.8%) | 29 (44.6%) | |
| Neoadjuvant Therapy | |||
| Group 1 | 37 (17.0%) | NA | |
| Group 2 | 71 (32.6%) | NA | |
| Group 3 | 72 (33.0%) | NA | |
| Group 4 | 32 (14.7%) | NA | |
| Group 5 | 6 (2.7%) | NA | |
| Median tumor size (range, cm) | 2.5 (0.1 – 8.5) | 3.0 (0.8–7.5) | 0.01 |
| Differentiation | 0.36 | ||
| Well | 1 (0.5%) | 2 (3.1%) | |
| Moderate | 135 (61.9%) | 42 (64.6%) | |
| Poor | 81 (37.2%) | 21 (32.3%) | |
| Margin | 0.50 | ||
| Negative | 195 (89.4%) | 56 (86.2%) | |
| Positive | 23 (10.6%) | 9 (13.8%) | |
| Lymph node status | 0.001 | ||
| Negative | 95 (43.6%) | 14 (21.5%) | |
| Positive | 123 (56.4%) | 51 (78.5%) | |
| Tumor stage (pT) | 0.21 | ||
| T0 | 1 (0.5%) | 0 (0%) | |
| T1 & T2 | 15 (6.9%) | 2 (3.1%) | |
| T3 | 202 (92.6%) | 62 (95.4%) | |
| T4 | 0 (0%) | 1 (1.5%) | |
| AJCC Stage | 0.000 | ||
| 0 | 1 (0.5%) | 0 (0%) | |
| IA & IB | 12 (5.5%) | 2 (3.1%) | |
| IIA | 82 (37.6%) | 12 (18.5%) | |
| IIB | 123 (56.4%) | 47 (72.3%) | |
| IV | 0 (0%) | 4 (6.2%) |